Neuroimmune Modulation Through Vagus Nerve Stimulation Reduces Inflammatory Activity in Crohn's Disease Patients: A...

Area of Science:

• Neuroimmunology
• Gastroenterology
• Medical Devices

Background:

• Crohn's disease (CD) is a chronic gastrointestinal inflammatory condition with limited treatment options.
• Current therapies achieve sustained remission in less than half of patients.
• The vagus nerve's 'inflammatory reflex' shows immunoregulatory potential, previously observed in rheumatoid arthritis and biologic-naive CD.

Purpose of the Study:

• To investigate the safety and efficacy of vagus nerve stimulation (VNS) in patients with treatment-refractory CD.
• To explore VNS as a novel therapeutic approach for managing moderate to severe CD.
• To assess clinical, endoscopic, molecular, and patient-reported outcomes of VNS in CD.

Main Methods:

• An open-label, multicentre clinical trial involving 17 patients with biologic drug-refractory CD.
• Vagus nerve stimulator implantation followed by 16 weeks of induction and 24 months of maintenance treatment.
• Evaluation of clinical improvement, patient-reported outcomes, endoscopic and molecular markers of inflammation, and safety.

Main Results:

• A statistically significant reduction in CD Activity Index (CDAI) and fecal calprotectin levels.
• Observed decrease in mucosal inflammation in a majority of patients with paired endoscopies.
• Reduced serum levels of pro-inflammatory cytokines (TNF and IFN-γ) and improved quality of life in some patients.

Conclusions:

• Vagus nerve stimulation (VNS) demonstrates safety and tolerability in patients with treatment-refractory Crohn's disease.
• VNS leads to clinically meaningful reductions in disease activity, endoscopic inflammation, and key inflammatory markers.
• Neuroimmune modulation via VNS presents a promising therapeutic strategy for Crohn's disease management.